BeOne has received approval in China for Amgen's lung cancer drug, Imdelltra.

Amgen reported positive late-stage clinical trial results for its subcutaneous drug, Tepezza, indicating promising developments for its efficacy.

The FDA has announced that Amgen's drug Tavneos has been linked to instances of liver injuries and fatalities.

The FDA has issued a warning regarding Amgen's drug Tavneos following reports of serious liver injury cases associated with its use.

Citi has increased its price target for Merck & Co. (MRK) to $125 from $120.

Amgen and GSK are said to be adding their products to the TrumpRx platform, indicating a potential expansion of the initiative's pharmaceutical offerings.

An article compares Novo Nordisk and Amgen as potential investment options in the weight loss stock market.

Amgen Announces 2026 Second Quarter Dividend  TradingView

The 2026 Amgen Irish Open will be held at the Trump International Golf Links & Hotel, Doonbeg, Co Clare.

Wall Street analysts are sharing their perspectives and expectations for Amgen Inc. (AMGN).

Amgen (AMGN) is being considered among the most profitable value stocks that investors should look to buy right now.

An analysis evaluates whether Amgen Inc. (AMGN) stands out as one of the top pharmaceutical stocks currently available for investment.

The U.S. Food and Drug Administration (FDA) has stated that Amgen's drug Tavneos has been linked to cases of liver injuries and deaths, as reported by the Wall Street Journal.

The Zacks Analyst Blog offers a detailed analysis of key companies including Roche Holding, AT&T, and Amgen, covering their market performance and future prospects.

Billionaire investor Ken Fisher has significantly increased his bullish position in Amgen Inc. (AMGN), doubling his stake in the biotechnology company.

Wall Street analysts have issued new ratings for biopharma companies, with Gilead receiving a 'Buy' recommendation, Amgen a 'Hold', and ORIC gaining a vote of confidence.

Oppenheimer has highlighted several stocks, including Apple (AAPL), Alcoa (AA), Baker Hughes (BKR), and Amgen (AMGN), as top performers for momentum.

An article analyzes whether Amgen stock is currently outperforming the Dow Jones Industrial Average, focusing on its market performance.

Stifel analysts are evaluating Viridian's prospects for market differentiation following the release of new data from Amgen, suggesting a potential path forward for the company.

The US FDA has issued a warning regarding cases of liver injury associated with a rare disease drug manufactured by Amgen.

The U.S. Food and Drug Administration (FDA) has confirmed that Amgen's drug Tavneos is linked to cases of liver injuries and deaths, as reported by the Wall Street Journal.

Teva Pharmaceutical Industries has received approval for its biosimilar version of Amgen's osteoporosis drug, Prolia.

Amgen has declared a dividend of $2.52 per share.

An analysis presenting a bullish investment case for Amgen Inc. (AMGN).

Barclays has begun coverage of Amgen, noting a balanced outlook despite ongoing debate surrounding its trials.